The Italian multinational company has acquired the specialist ophthalmology company as part of a £130 million series of investments into high-potential markets. 

Italian multinational company Fidia Farmaceutici has acquired all of the share capital of British specialist ophthalmology company Altacor. 

The acquisition will expand the company’s operational footprint and, the company said, represents a significant milestone in Fidia’s international growth strategy, which aims to create synergies in operations and distribution across high-potential markets and therapeutic segments.

The acquisition will allow Fidia to develop Altacor’s existing portfolio, specifically Clinitas, a dedicated line for dry eye treatment. At the same time, the company has said that it intends to introduce its own products to the British market, including a range of artificial tears formulated with its patented Fidia hyaluronic acid (FHA 1.0). This has been designed to address different forms of dry eye disease, as well as diagnostic stains for ocular surface diseases, a comprehensive line of ophthalmic food supplements and multiple platforms to support cataract and corneal crosslinking surgeries.

High-potential markets

Financial terms have not been disclosed, though the company said that this acquisition is part of a broader €150 million (£130 million) investment plan for 2025-26. Last year, Fidia reported revenues exceeding €500 million, up 10.1% year-on-year, with double-digit growth across all key markets. 

“Building on a series of strategic M&A operations completed in recent years, the acquisition of Altacor represents another milestone in our international growth journey,” said Carlo Pizzocaro, president and chief executive of Fidia Farmaceutici.

“We are increasingly focusing our investments on high-potential markets, such as the UK, to strengthen our global presence and expand into new therapeutic areas. By broadening our product portfolio and gaining access to complementary channels, we will further reinforce our position as a leading international player, delivering innovative and effective solutions to meet patient needs in every country where we operate,” he added.

Fidia was advised by McDermott Will & Emery on the legal aspects of the Altacor acquisition and by EY Tax & Law on tax aspects.